Beranda › Leukemia Mieloid Fase Kronis › California
Uji klinis Leukemia Mieloid Fase Kronis di California
5 studi untuk Leukemia Mieloid Fase Kronis mencari peserta di lokasi di California.
Teks studi resmi (Bahasa Inggris)
Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1062, Duarte
- Ascentage Investigative Site #1099, Irvine
- Ascentage Investigative Site #1075, La Jolla
- dan 4 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06423911A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT07020533A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Stockton Hematology Oncology Medical Group Inc, Stockton
- Lundquist Inst BioMed at Harbor, Torrance
Menerima pesertaStudi observasional
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT07091019Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Mar 2026 · NCT06229860A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- UC Irvine Health, Orange
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT06163430Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.